US2007185181A1PendingUtilityA1

Treatment or prevention of hypotension and shock

52
Assignee: ORION CORPPriority: Oct 29, 1999Filed: Dec 20, 2006Published: Aug 9, 2007
Est. expiryOct 29, 2019(expired)· nominal 20-yr term from priority
Inventors:Riitta HeinoTiina LeinoTarja Lehtimaki
A61P 9/02A61P 9/00A61P 11/00A61K 31/415A61K 9/0019A61K 31/4164
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof, and a method for the treatment of cardiopulmonary resuscitation, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled)  
   
   
       15 . A method for treating a mammal that has or is at risk for hypotension due to low peripheral resistance or shock due to low peripheral resistance, comprising administering to the mammal an effective amount of at least one imidazole derivative of formula I:  
     
       
         
         
             
             
         
       
     
     wherein R is hydrogen or methyl, or a pharmaceutically acceptable ester or salt thereof.  
   
   
       16 . A method for effecting cardiopulmonary resuscitation, comprising administering to a mammal in need thereof an effective amount of at least one imidazole derivative of formula I  
     
       
         
         
             
             
         
       
     
     wherein R is hydrogen or methyl, or a pharmaceutically acceptable ester or salt thereof.  
   
   
       17 . The method according to  claim 15 , wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol is administered.  
   
   
       18 . The method according to  claim 15 , wherein 3-(1 H-imidazol-4-ylmethyl)-indan-5-ol hydrochloride is administered.  
   
   
       19 . The method according to  claim 15 , wherein the administration is intravenous.  
   
   
       20 . The method according to  claim 15 , wherein the mammal is a human.  
   
   
       21 . The method according to  claim 19 , wherein the effective amount administered is from about 10 to about 500 μg/patient.  
   
   
       22 . The method according to  claim 21 , wherein the effective amount administered is from about 30 to about 200 μg/patient.  
   
   
       23 . The method according to  claim 20 , wherein the effective amount administered is from about 10 to about 500 μg/patient.  
   
   
       24 . The method according to  claim 23 , wherein the effective amount administered is from about 30 to about 200 μg/patient.  
   
   
       25 . The method according to  claim 16 , wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol is administered.  
   
   
       26 . The method according to  claim 16 , wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol hydrochloride is administered.  
   
   
       27 . The method according to  claim 16 , wherein the administration is intravenous.  
   
   
       28 . The method according to  claim 16 , wherein the mammal is a human.  
   
   
       29 . The method according to  claim 27 , wherein the effective amount administered is from about 10 to about 500 μg/patient.  
   
   
       30 . The method according to  claim 29 , wherein the effective amount administered is from about 30 to about 200 μg/patient.  
   
   
       31 . The method according to  claim 28 , wherein the effective amount administered is from about 10 to about 500 μg/patient.  
   
   
       32 . The method according to  claim 31 , wherein the effective amount administered is from about 30 to about 200 μg/patient.

Join the waitlist — get patent alerts

Track US2007185181A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.